{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-084154","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.764083+00:00","generated_at":"2026-05-15T22:33:37.937772+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"EyePoint doses first patients in Phase 3 DME trials for DURAVYU; topline data 2H 2027","bullets":["First patients dosed in global Phase 3 COMO and CAPRI trials of DURAVYU (vorolanib intravitreal insert) for diabetic macular edema.","DURAVYU is a sustained-release TKI inhibiting VEGF, PDGF, and IL-6; design based on positive Phase 2 VERONA results.","Non-inferiority trials vs aflibercept; ~240 patients each; primary endpoint BCVA change at weeks 52 and 56.","DURAVYU 2.7mg administered via standard intravitreal injection every six months; topline data anticipated 2H 2027.","Program aligns with FDA and EMA after End of Phase 2 meeting; aims to reduce treatment burden for DME patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-084154","json":"https://secwatch.observer/filing/0001193125-26-084154.json","markdown":"https://secwatch.observer/filing/0001193125-26-084154.md","text":"https://secwatch.observer/filing/0001193125-26-084154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526084154/0001193125-26-084154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526084154/eypt-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:33:37.937772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}